European Prostate Cancer Screening Study: 23-Year Follow-Up
“`html
RSV Vaccine Breakthrough: A New Shield for infants and Older Adults
Understanding the RSV Threat
Respiratory Syncytial Virus (RSV) is a pervasive and often underestimated respiratory pathogen. While often causing mild, cold-like symptoms, RSV can lead to serious complications, notably in infants, young children, and older adults. Before the advent of these vaccines, RSV was the leading cause of bronchiolitis and pneumonia in infants under one year of age, and a significant contributor to hospitalizations in older adults.The virus spreads through respiratory droplets produced when an infected person coughs or sneezes.
historically, managing RSV has been largely supportive, focusing on symptom relief and preventing dehydration. Ribavirin, an antiviral medication, exists but is reserved for severe cases due to its potential side effects and limited efficacy. Palivizumab, a monoclonal antibody, is available for high-risk infants, but it’s expensive and requires monthly governance during RSV season.
The Landmark Vaccine Approvals
In May 2023, the Food and Drug Administration (FDA) approved two groundbreaking RSV vaccines: Arexvy, developed by GSK, and Abrysvo, created by Pfizer. These vaccines represent a paradigm shift in RSV prevention, offering a proactive approach to protecting those most vulnerable.
Arexvy (GSK): Approved for adults aged 60 years and older, Arexvy utilizes a recombinant subunit vaccine technology. Clinical trials demonstrated approximately 82.6% efficacy in preventing RSV-associated LRTD with a symptom burden score of 3 or greater. The vaccine works by presenting a stabilized prefusion F protein, triggering an immune response that prepares the body to fight off the virus.
Abrysvo (Pfizer): Abrysvo received a broader approval, encompassing both older adults (60 years and older) and pregnant individuals. For pregnant people, Abrysvo is administered between 32 and 36 weeks of gestation, providing passive immunity to the newborn through maternal antibody transfer. Clinical trials showed approximately 77.3% efficacy in preventing RSV-associated LRTD in infants born to vaccinated mothers. For older adults, Abrysvo demonstrated approximately 66.3% efficacy against RSV-associated LRTD.
Clinical Trial Data: A Closer Look
| Vaccine | Target Population | Efficacy (LRTD) | Technology |
|---|---|---|---|
| Arexvy (GSK) | Adults 60+ | 82.6% | Recombinant Subunit |
| Abrysvo (Pfizer) | Adults 60+ | 66.3% | mRNA |
| Abrysvo (Pfizer) | Infants (via maternal vaccination) | 77.3% | mRNA |
Data from the pivotal clinical trials, published in the New England Journal of Medicine (October 30, 2025